Combination with immune checkpoint inhibitors

VCN Biosciences scientists have recently combined an oncolytic adenovirus with an anti-PD1 antibody in an immunocompetent murine model to enhance anti-tumor immunity. Their results have shown that even in a poorly permissive model for adenovirus replication, the combination treatment enhanced anti-tumor activity with respect to any single treatment alone, both in injected tumors and in contralateral non-injected tumors, describing complete tumor regressions. 
Different experiments are currently on-going exploring this approach to obtain further evidence to initiate clinical validation.